Artificial Cells for Use in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 1490
Special Issue Editors
Interests: artificial cells; biomaterials; blood substitutes; drug delivery; microencapsulation; enzyme engineering
Interests: blood substitutes; blood transfusions; e-cigarettes and vaping; hemoglobins; nitric oxide; portable nitric oxide generator; pulmonary and systemic vasoconstriciton; therapeutic nitric oxide; transfusion safety
Special Issue Information
Dear Colleagues,
The goal of this series is to connect the different branches of this highly interdisciplinary area through publications spread over many different specialty journals so that information can be available to all those involved in cancer research.
It is only in recent years that the original idea of artificial cells has been extensively explored and developed.
Artificial cell configuration has evolved into bioencapsulation, nanoparticles, nanocapsules, PEG proteins, liposomes, biodegradable nanoparticles, synthetic cells, and others. Its first use in cancer therapy was shown in 1971 using artificial cells containing asparaginase to suppress lymphosarcoma in mice. Others have extended this to PEG-asparaginase for leukemia in patients. Targeting has been carried out using surface ligands or magnetic properties, surface charges, polysaccharides, antibodies, and polyethylene glycol (PEG). Polylactide (PLA) artificial cells containing PolyHb-tyrosinase have been found to be effective in suppressing the growth of melanoma in a mice model. Polylactide PLA is biodegradable and FDA-approved and has been used to prepare artificial cells, and it has been developed extensively worldwide in the form of PLGA nanoparticles, polymersomes, and nanocapsules. Docetaxel-loaded PLGA nanoparticles have been found to improve efficacy in taxane-resistant triple-negative breast cancer, while another group has reported the use of nanoparticles in cancer detection via Raman-scattering-based techniques. Lysozyme and DNAse-loaded poly biodegradable nanocapsules have also been used.
Dr. Thomas Ming Swi Chang
Guest Editor
Dr. Binglan Yu
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- artificial cells
- drug delivery
- nanomedicine
- nanobiotherapeutic
- biotechnology
